Gara Jalqabaatti › Leukemia › Massachusetts
Qorannoo klinikaalii Leukemia Massachusetts keessatti
Qorannoo 28 Leukemia f Massachusetts keessatti hirmaatuu jiru.
Magaalota Massachusetts keessatti
Takkalaa qorannoo (Ingiliffa)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT04996875Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 18 · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT07249346CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 90 · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT07439211Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT06001788ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 51 · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT07227584Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Mass General Brigham Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Ado-2026 · NCT07671209Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ado-2026 · NCT06469307Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 19 hanga 110 · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Wax-2026 · NCT05475925A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 17-Wax-2026 · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Wax-2026 · NCT06138587A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Cam-2026 · NCT03219450Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 18-Cam-2026 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Elb-2026 · NCT04256317Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Elb-2026 · NCT05646576Shwachman Diamond Syndrome Registry and Study
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 06-Elb-2026 · NCT06056908Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 25-Bit-2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT05735184Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Gur-2026 · NCT06644183A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Gur-2026 · NCT07148180Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Mud-2025 · NCT07052695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2025 · NCT05842603HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2025 · NCT06487247Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.